SCHEMBL5542523

SCHEMBL5542523

CC(O)(CCN1CCN(C(=O)OC(C)(C)C)CC1)Cn1cc([N+](=O)[O-])nc1Cl

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.41
LMNA P02545 1/20 0.41
MAPT P10636 1/20 0.41
VEGFA P15692 1/20 0.38
EGLN1 Q9GZT9 1/20 0.38
POLB P06746 1/20 0.37
KCNH2 Q12809 1/20 0.37
SUV39H2 Q9H5I1 2/20 0.36
ACKR3 P25106 4/20 0.35
HTT P42858 1/20 0.35
ATM Q13315 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
STS P08842 1/20 0.35
CHRM2 P08172 1/20 0.35
CHRM4 P08173 1/20 0.35
CHRM1 P11229 1/20 0.35
CHRM3 P20309 1/20 0.35
TLR8 Q9NR97 1/20 0.35
MAP4K4 O95819 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6010609 0.91 ALDH1A1 (0.43) ALDH1A1LMNAMAPTVEGFAEGLN1
SCHEMBL6010636 0.91 ALDH1A1 (0.43) ALDH1A1LMNAMAPTVEGFAEGLN1
SCHEMBL5541421 0.91 ALDH1A1 (0.43) ALDH1A1LMNAMAPTVEGFAEGLN1
SCHEMBL27629324 0.88 LMNA (0.37) ALDH1A1LMNAPOLBKCNH2KMT2A
SCHEMBL5542233 0.88 MEN1 (0.41) ALDH1A1LMNAMAPTVEGFAEGLN1
SCHEMBL5539813 0.87 ALDH1A1 (0.42) ALDH1A1LMNAMAPTVEGFAEGLN1
SCHEMBL5539803 0.87 ALDH1A1 (0.42) ALDH1A1LMNAMAPTVEGFAEGLN1
SCHEMBL6010674 0.81 ABCB1 (0.44) ALDH1A1LMNAMAPTVEGFAEGLN1
SCHEMBL5535042 0.81 ABCB1 (0.44) ALDH1A1LMNAMAPTVEGFAEGLN1
SCHEMBL6010797 0.81 ABCB1 (0.44) ALDH1A1LMNAMAPTVEGFAEGLN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 ALDH1A1 355/4885LMNA 4152/4885MAPT 4117/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.